Stephan A Grupp Selected Research

Chimeric Antigen Receptors

10/2022	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL.
4/2022	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
1/2022	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.
1/2022	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
1/2022	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
1/2022	Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.
1/2022	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
10/2021	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
10/2021	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
5/2021	CAR-T cells: Early successes in blood cancer and challenges in solid tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephan A Grupp Research Topics

Disease

63	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 08/2002
54	Neoplasms (Cancer) 01/2022 - 03/2004
29	Leukemia 01/2022 - 01/2003
26	Cytokine Release Syndrome 01/2022 - 04/2013
19	Neuroblastoma 01/2020 - 03/2004
18	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2011
9	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 08/2011
8	Lymphoma (Lymphomas) 05/2021 - 12/2003
6	Residual Neoplasm 01/2022 - 09/2009
6	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2021 - 03/2016
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 12/2009
5	Autoimmune Lymphoproliferative Syndrome 01/2016 - 09/2006
4	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
4	Infections 01/2021 - 03/2015
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 02/2010
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 10/2012
3	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 02/2010
3	Splenomegaly 01/2016 - 02/2006
3	Cytopenia 01/2016 - 03/2010
3	Lymphadenopathy 01/2016 - 09/2006
3	Macrophage Activation Syndrome 09/2014 - 02/2014
3	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 09/2009 - 08/2002
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2022 - 01/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 07/2022 - 01/2017
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021 - 01/2018
2	Fever (Fevers) 10/2021 - 02/2017
2	Hemorrhage 01/2021 - 03/2016
2	Hypersensitivity (Allergy) 11/2020 - 09/2010
2	COVID-19 11/2020 - 01/2020
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2018 - 06/2009
2	Multiple Myeloma 01/2018 - 01/2018
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 06/2009
2	Hyperferritinemia 02/2017 - 06/2013
2	Pneumonia (Pneumonitis) 01/2015 - 01/2013
2	Body Weight (Weight, Body) 10/2014 - 04/2013
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2012 - 06/2009
2	Bronchiolitis Obliterans Syndrome 01/2012 - 12/2011
1	Down Syndrome (Down's Syndrome) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 10/2021

Drug/Important Bio-Agent (IBA)

59	Chimeric Antigen ReceptorsIBA 10/2022 - 08/2011
26	tisagenlecleucelIBA 01/2022 - 04/2013
14	CytokinesIBA 11/2020 - 01/2008
13	AntigensIBA 01/2020 - 08/2009
10	Sirolimus (Rapamycin)FDA Link 01/2016 - 01/2003
9	tocilizumab (atlizumab)FDA Link 01/2022 - 04/2013
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
7	Monoclonal AntibodiesIBA 01/2018 - 09/2010
6	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2014
6	defibrotideIBA 01/2021 - 03/2016
6	RNA (Ribonucleic Acid)IBA 01/2018 - 03/2004
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2006
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2019 - 08/2011
5	Surface Antigens (Surface Antigen)IBA 10/2018 - 01/2012
4	blinatumomabIBA 01/2022 - 06/2013
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 03/2010
4	AntibodiesIBA 01/2016 - 01/2008
4	TOR Serine-Threonine KinasesIBA 10/2012 - 12/2003
4	MTOR InhibitorsIBA 10/2012 - 10/2007
3	CD19 AntigensIBA 01/2022 - 12/2014
3	Messenger RNA (mRNA)IBA 01/2021 - 12/2011
3	Phosphotransferases (Kinase)IBA 12/2017 - 08/2012
2	siltuximabIBA 01/2022 - 01/2016
2	Interleukin-10 (Interleukin 10)IBA 11/2020 - 01/2017
2	Biological ProductsIBA 10/2020 - 09/2014
2	CD19-specific chimeric antigen receptorIBA 01/2020 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2008
2	Death Domain ReceptorsIBA 01/2020 - 12/2010
2	Pharmaceutical PreparationsIBA 11/2019 - 01/2019
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 03/2004
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 08/2002
2	Bispecific AntibodiesIBA 07/2014 - 02/2014
2	Interleukin-2 (IL2)IBA 05/2014 - 09/2010
2	InterleukinsIBA 03/2014 - 02/2014
2	InterferonsIBA 03/2014 - 02/2014
2	Isotretinoin (Accutane)FDA LinkGeneric 09/2013 - 09/2010
2	Etanercept (Enbrel)FDA Link 04/2013 - 01/2013
2	Tacrolimus (Prograf)FDA LinkGeneric 04/2013 - 12/2009
2	temsirolimus FDA Link 07/2011 - 02/2006
2	Methotrexate (Mexate)FDA LinkGeneric 12/2009 - 09/2008
2	SurvivinIBA 12/2006 - 03/2004
2	SteroidsIBA 01/2003 - 08/2002
1	CytosineIBA 11/2022
1	ProteomeIBA 01/2022
1	EmapalumabIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	GlucocorticoidsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022

Therapy/Procedure

67	Therapeutics 07/2022 - 08/2002
24	Immunotherapy 01/2022 - 03/2004
12	Hematopoietic Stem Cell Transplantation 01/2019 - 02/2010
11	Drug Therapy (Chemotherapy) 01/2022 - 12/2012
8	Stem Cell Transplantation 01/2021 - 09/2009
7	Transplantation 01/2022 - 06/2006
7	Cell Transplantation 01/2021 - 12/2009
6	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 02/2010
4	Induction Chemotherapy 01/2020 - 11/2012
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2020 - 09/2013
2	Radiotherapy 01/2020 - 09/2013